Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
BRAF V600X
|
melanoma
|
sensitive |
ASN003
|
Preclinical - Pdx |
Actionable |
In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)).
|
detail...
|
BRAF V600E
|
melanoma
|
sensitive |
ASN003
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).
|
detail...
|
Unknown unknown
|
Advanced Solid Tumor
|
not applicable |
ASN003
|
Phase I |
Actionable |
In a Phase I trial, ASN003 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 371PD; NCT02961283).
|
detail...
|
BRAF V600E PTEN mut
|
melanoma
|
sensitive |
ASN003
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).
|
detail...
|